Versus 6(对 6)研究综述
Versus 6 对 6 - 0% versus 65. [1] 0 versus 64. [2] 7% versus 61. [3] 9% versus 6. [4] Teens were more likely to request information than their parents (79% versus 65% requesting at least one item) particularly in regard to pregnancy/contraception and insurance. [5] 9 years versus 6. [6] Nephrographic ALAD was able to differentiate chromophobe RCC from oncocytoma in the training and validation cohorts with a sensitivity of 100% versus 67%, specificity of 86% versus 67%, PPV of 75% versus 43%, and NPV of 100% versus 84%. [7] Methods A total of 96 patients who received IM nailing with or without supportive poller screw for treating long-bone fractures in lower limbs and who experienced difficulties in performing reduction or IM insertion during the surgical process were included in this retrospective cohort study (33 patients with poller screws in group A versus 63 patients without poller screws in group B). [8] 5 d), ICU LOS (11 versus 8 d), rate of primary closure (66% versus 56%), post op ileus (44% versus 48%), abscess (14% versus 10%), need for surgery after closure (32% versus 19%), anastomotic dehiscence (16% versus 6%), or mortality (34% versus 42%). [9] Results Our replicated models predicted TRD in the STAR*D dataset with slightly better balanced accuracy than Nie et al (70%-73% versus 64%-71%, respectively). [10] 5% versus 65. [11] However, the imaging-to-puncture delay in the MT group did not differ according to the occurrence of PH: 51 minutes (interquartile range [IQR] = 44–74) versus 63 minutes (IQR = 45–78) in patients with versus without PH, respectively (p = 0. [12] 5 years versus 68. [13] 02) and dyspnoea (43% versus 6%, P < 0. [14] 6) versus 6. [15] 82 progression-free life-years with iStent inject® versus 6. [16] Four comparison studies with IMRT found significantly lower feeding tube rates (20% versus 65%, P =. [17] History of psychiatric diagnoses or previous suicide attempts was more frequent in SISWs (47% versus 6. [18] 6% versus 63. [19] La proportion de TC positifs etait significativement plus importante lorsque la reaction initiale etait recente (moins de 5 ans) (15,6 % versus 6 % ; p = 0,007) ou severe (grade 2 et 3) (27 % VS 6,6 % ; p Conclusion La VPN de nos TC est satisfaisante mais est inferieure a celle retrouvee dans la litterature. [20] The proportion of patients experiencing skin hypopigmentation in the EPB subcompartment group was lower than in the both-subcompartment group (33% [8 of 24] versus 67% [16 of 24]; odds ratio 0. [21] 5% versus 6. [22] 0 versus 67. [23] 41 years (24–68 years) versus 61. [24] Successful conversion to full-text articles was similar for male and female presenters (68% versus 62%, P = 0. [25] 9% versus 690. [26] Results Completion rates were similar between video and clinic visits (58% versus 61%, respectively; p=0. [27] 02) and higher mortality (43% versus 67%, p = 0. [28] 1% versus 6. [29] 5% versus 6. [30] The expression of HNF-1β was greater in iCCA and the CCA component of cHCC-CCA compared with CRP (87 of 87, 100% versus 65 of 86, 75. [31] 77 % versus 6. [32] In addition, the combination therapy with immunomodulators (IMM) was less frequent in the DIL group (0% versus 64. [33] 8% versus 6. [34] In arm B, mean best corrected visual acuity improved from 6/398 to 6/177, versus 6/147 to 6/144 in the fellow eye. [35] 0% versus 63. [36] 001) and phosphate intake (927 [485] versus 697 [434] mg/d; P =. [37] 9% versus 60. [38] 1 years versus 6. [39] 6% versus 69. [40] 3% versus 64. [41] 014), a higher prevalence of low global circumferential strain (36% versus 64%, P=0. [42] 7% versus 68%). [43] Although most begin with the utilization of NSAIDs and non-opioid analgesics, followed by ESI (88%), surgery was recommended for persistent symptoms/signs for those failing between 3 and 6 weeks (private sector) versus 6–12 weeks (public sector) of conservative therapy. [44] 5% versus 67. [45] 6% versus 66. [46] 5% versus 65% in patients ≤65 years. [47] 6% versus 65. [48] 2% versus 65. [49] 8) versus 63. [50]0% 对 65。 [1] 0 对 64。 [2] 7% 对 61。 [3] 9% 对 6。 [4] 与父母相比，青少年更有可能要求提供信息（79% 对 65% 要求至少一项），尤其是在怀孕/避孕和保险方面。 [5] 9 年对 6 年。 [6] 肾造影 ALAD 能够在训练和验证队列中区分嫌色细胞 RCC 和嗜酸细胞瘤，灵敏度分别为 100% 和 67%，特异性分别为 86% 和 67%，PPV 分别为 75% 和 43%，NPV 分别为 100% 和 84% . [7] 方法 回顾性队列研究共纳入 96 例接受 IM 钉加或不加支持性 Poller 螺钉治疗下肢长骨骨折，并在手术过程中进行复位或 IM 置入困难的患者（33 例A组中的轮询器螺钉与B组中没有轮询器螺钉的63名患者）。 [8] 5 天）、ICU LOS（11 天对 8 天）、初次闭合率（66% 对 56%）、肠梗阻后（44% 对 48%）、脓肿（14% 对 10%）、闭合后需要手术（32% 对 19%）、吻合口裂开（16% 对 6%）或死亡率（34% 对 42%）。 [9] 结果 我们的复制模型在 STAR*D 数据集中预测 TRD 的平衡精度略高于 Nie 等人（分别为 70%-73% 和 64%-71%）。 [10] 5% 对 65。 [11] 然而，MT 组的成像到穿刺延迟没有因 PH 的发生而不同：51 分钟（四分位距 [IQR] = 44-74）与 63 分钟（IQR = 45-78）相比分别没有 PH (p = 0. [12] 5 年与 68 年。 [13] 02）和呼吸困难（43% 对 6%，P < 0。 [14] 6) 对 6。 [15] iStent injection® 的无进展生命年为 82 年，而 iStent 注射剂为 6 年。 [16] 与 IMRT 进行的四项比较研究发现饲管率显着降低（20% 对 65%，P =. [17] 在 SISW 中，精神病诊断史或先前的自杀企图更为常见（47% 对 6. [18] 6% 对 63。 [19] 当初始反应是近期（少于 5 年）（15.6% 对 6%；p = 0.007）或严重（2 级和 3 级）（27% 对 6.6%；p 结论 NPV我们的 TC 的值令人满意，但低于文献中的值。 [20] EPB 亚室组中出现皮肤色素减退的患者比例低于双亚室组（33% [8 of 24] vs 67% [16 of 24]；优势比为 0。 [21] 5% 对 6。 [22] 0 对 67。 [23] 41 岁（24-68 岁）与 61 岁。 [24] 男性和女性演讲者成功转换为全文文章的比例相似（68% 对 62%，P = 0。 [25] 9% 对 690。 [26] 结果 视频访问和诊所访问的完成率相似（分别为 58% 和 61%；p=0。 [27] 02）和更高的死亡率（43% 对 67%，p = 0。 [28] 1% 对 6。 [29] 5% 对 6。 [30] 与 CRP 相比，iCCA 和 cHCC-CCA 的 CCA 成分中 HNF-1β 的表达更高（87 例中的 87, 100% 对 86 例中的 65 例, 75. [31] 77% 对 6。 [32] 此外，在 DIL 组中与免疫调节剂 (IMM) 联合治疗的频率较低（0% 对 64.0%）。 [33] 8% 对 6。 [34] 在 B 组中，平均最佳矫正视力从 6/398 提高到 6/177，而对侧眼从 6/147 提高到 6/144。 [35] 0% 对 63。 [36] 001）和磷酸盐摄入量（927 [485] 对 697 [434] 毫克/天；P =。 [37] 9% 对 60。 [38] 1 年对 6 年。 [39] 6% 对 69。 [40] 3% 对 64。 [41] 014），较低的全球周向应变的患病率较高（36% 对 64%，P=0。 [42] 7% 对 68%）。 [43] 虽然大多数人从使用非甾体抗炎药和非阿片类镇痛剂开始，其次是 ESI (88%)，但对于那些在 3 至 6 周（私营部门）与 6-12 周（公共部门）之间失败的持续症状/体征，建议进行手术) 的保守治疗。 [44] 5% 对 67。 [45] 6% 对 66。 [46] ≤65 岁的患者中为 5% 和 65%。 [47] 6% 对 65。 [48] 2% 对 65。 [49] 8) 对 63。 [50]
% 95 % % 95 %
VE was higher for non-VOC than VOC (73% Alpha) among single-dose (77%, 95%CI: 73-81 versus 63%, 95%CI: 57-67) but not two-dose recipients (87%, 95%CI: 57-96 versus 94%, 95%CI: 89-96). [1] 4%) versus 63% (95% CI 41. [2] VE was higher for non-VOC than VOC (73% Alpha) among single-dose (77%, 95%CI: 73-81 versus 63%, 95%CI: 57-67) but not two-dose recipients (87%, 95%CI: 57-96 versus 94%, 95%CI: 89-96). [3] By anti-VEGF, the closure rate was 98% (95% CI [93 ~ 100%]), the VA improved in 90% (95% CI [74 ~ 100%]) of the patients, and the VA of 58% (95% CI [18 ~ 94%]) hemorrhagic versus 67% (95% CI [31 ~ 96%]) exudative patients improved significantly. [4] A mean proportion of 40·6% (SD 14·5) of eligible children younger than 5 years in the control arm received an MRDT, versus 66·7% (11·7) in the social group arm (adjusted risk difference [aRD] 28·8%, 95% CI 21·9-35·7, p<0·0001) and 71·7% (19·8) in the social group plus provider arm (aRD 32·7%, 24·9-40·5, p<0·0001), with no significant difference between the social group arm and the social group plus provider arm. [5] Using 1,945,071 real-time PCR results from nose and throat swabs taken from 383,812 participants between 1 December 2020 and 8 May 2021, we found that vaccination with the ChAdOx1 or BNT162b2 vaccines already reduced SARS-CoV-2 infections ≥21 d after the first dose (61% (95% confidence interval (CI) = 54–68%) versus 66% (95% CI = 60–71%), respectively), with greater reductions observed after a second dose (79% (95% CI = 65–88%) versus 80% (95% CI = 73–85%), respectively). [6] In intention-to-treat analysis, the average percentage of weekly opioid negative UDT was 50 % (95 % CI: 40-63 %) in the intervention arm versus 64 % (95 % CI: 55-74 %) among controls; RR = 0. [7] In 2018, the 90-90-90 indicators were: 93%-97%-95% (versus 60%-68%-83% in 2012). [8] The risk of drug-related death at 12 months among patients in post-discharge OUD care was 3% (95% CI = 0%, 7%) versus 6% not in care (95% CI = 2%, 10%). [9] Eighty-eight percent of pilot participants reported White race (95%CI: 81%-95%), versus 67% of the comparison population (N=2,065). [10] Heterogeneity analysis showed that sensitivity of MRI performed with evacuation phase was higher than without for rectocele (94%, CrI 87%-98%) versus 65%, CrI 52% to 89%, and enterocele (87%, CrI 74%-95% versus 62%, CrI 51%-88%), and sensitivity of MRI without evacuation phase was significantly lower than EP. [11]在单剂量接受者（77%，95%CI：73-81 对比 63%，95%CI：57-67）中，非 VOC 的 VE 高于 VOC（73% Alpha），但在接受两次剂量接受者中则不然（87% , 95%CI: 57-96 对比 94%, 95%CI: 89-96)。 [1] 4%) 与 63% (95% CI 41)。 [2] 在单剂量接受者（77%，95%CI：73-81 对比 63%，95%CI：57-67）中，非 VOC 的 VE 高于 VOC（73% Alpha），但在接受两次剂量接受者中则不然（87% , 95%CI: 57-96 对比 94%, 95%CI: 89-96)。 [3] nan [4] nan [5] nan [6] 在意向治疗分析中，干预组每周阿片类药物阴性 UDT 的平均百分比为 50 %（95 % CI：40-63 %），而对照组为 64 %（95 % CI：55-74 %）； RR = 0。 [7] nan [8] nan [9] nan [10] nan [11]
progression free survival 无进展生存期
Compared to lymph node-negative patients, the 77 patients with lymph node metastasis had significantly lower overall, (55% versus 68%), disease-specific (64% versus 86%), and progression-free survival (51% versus 77%), mainly due to non-local recurrences including a high number of paraaortic recurrences. [1] 13), progression-free survival (70% versus 61%, P = 0. [2] 02); better progression-free survival (PFS): 82% (77% to 87%) versus 69% (61% to 77%) (P <. [3] 1%, respectively, while progression free survival (PFS) at 4 years for RRMS and SPMS was 95% versus 66%, respectively. [4] At a median follow-up of 38 months after randomisation (IQR 24-50), 3-year progression-free survival was 80% (95% CI 70-87) in the lenalidomide group versus 64% (53-73) in the observation group (log-rank test p=0·012; hazard ratio 0·51, 95% CI 0·30-0·87). [5] Median hepatic progression-free survival (PFS) was 7 months in those with extrahepatic disease versus 6 months in those with isolated CRLM at the time of HAIP placement (p = 0. [6]与淋巴结阴性患者相比，77 名淋巴结转移患者的总体生存率（55% 对 68%）、疾病特异性（64% 对 86%）和无进展生存期（51% 对 77%）显着降低)，主要是由于非局部复发，包括大量的主动脉旁复发。 [1] 13），无进展生存期（70% 对 61%，P = 0。 [2] nan [3] nan [4] nan [5] nan [6]
% respectively p % 分别为 p
There was a higher incidence of poor anticoagulant response (ΔR < 1 min) with enoxaparin prophylaxis compared to heparin prophylaxis and intravenous heparin (84% versus 62% and 53%, respectively, p < 0. [1] Primary patency rates of pre-DES circuit (patency for last CBA) versus post-DES circuit at 6 and 12 months were 29% versus 64% and 7% versus 29%, respectively (p = 0. [2] , 39/55 (71%) versus 6/40 (15%), respectively (p<0. [3] 9% versus 62% respectively, p = 0. [4] , 39/55 (71%) versus 6/40 (15%), respectively (p < 0. [5] The global reduction in transplantation was higher in public institutions compared with private institutions, 89% versus 62%, respectively, p <. [6]与肝素预防和静脉肝素相比，依诺肝素预防的抗凝反应不良（ΔR < 1 分钟）的发生率更高（分别为 84% 和 62% 和 53%，p < 0。 [1] 在 6 个月和 12 个月时，DES 前回路（最后一次 CBA 的通畅）与 DES 后回路的主要通畅率分别为 29% 和 64% 和 7% 和 29%（p = 0. [2] nan [3] nan [4] nan [5] nan [6]
5 year overall 总共5年
001), 5-year overall survival was 86% versus 69%, respectively (HR 0. [1] The GCB-DLBCL was associated with inferior 5-year overall survival at 44% (95%CI, 36-52) versus 64% (95%CI, 54-77) (P =. [2] Regarding the impact of lymph node involvement, 5-year overall survival (OS) in patients with compromised lymph nodes was 32% versus 68% for patients without compromised lymph nodes (p = 0. [3] 0001), and unfavorable 5-year overall survival (44% versus 65% for positive/negative staining). [4]001), 5 年总生存率分别为 86% 和 69% (HR 0. [1] GCB-DLBCL 与较差的 5 年总生存率相关，分别为 44% (95%CI, 36-52) 和 64% (95%CI, 54-77) (P =. [2] nan [3] nan [4]
median interquartile range 中位数四分位距
Patients with a spot sign treated conservatively presented with larger hematoma volumes (median [interquartile range]: 26 [7–41] versus 6 [2–13], P=0. [1] Results HD and PD patients had similar troponin levels [median (interquartile range) troponin I: 25 ng/L (14–43) versus 21 ng/L (11–37), troponin T: 70 ng/L (44–129) versus 67 ng/L (43–123)]. [2] The preoperative maximum clot firmness was higher in patients with clinically evident VTE than in patients without these complications (median [interquartile range] 70 mm [68 to 71] versus 65 mm [61 to 68]; p < 0. [3] Results Differences (median [interquartile range]) were detected in age (76 [70–82] versus 66 [55–74] years), day from the onset of first symptoms to admission for mechanical ventilation (5 [3–7] versus 10 [8–12] days), and P/F ratio (i. [4]经保守治疗的斑点征患者血肿体积较大（中位数[四分位距]：26 [7-41] 对 6 [2-13]，P=0。 [1] 结果 HD 和 PD 患者的肌钙蛋白水平相似 [中位数（四分位距）肌钙蛋白 I：25 ng/L (14-43) 对比 21 ng/L (11-37)，肌钙蛋白 T：70 ng/L (44-129) ]. 与 67 ng/L (43–123)]。 [2] nan [3] nan [4]
% per year ％ 每年
They had more visits of all types (outpatient: 79% per year versus 64% per year [age‐adjusted OR, 2. [1] Specifically, we find that the probability of misclassifying a fund with a true alpha of 2% per year is 32% (versus 65% in AP). [2]他们有更多的各种类型的就诊（门诊：每年 79% 对每年 64% [年龄调整 OR，2. [1] nan [2]
% versus 17 % 与 17
PFS and OS at 3 years with and without LRT were 31% versus 6% (p < 0·001) and 41% versus 17% (p < 0·001), respectively. [1] Despite the fact that there were no statistically significant differences in the frequency of formation of dropsy of the testicle (0 (0,0%) versus 6 (1,3%), p=0,185), a statistically significantly better condition of patients was revealed as a result of the use of the innovative PHELPS technique, consisted in the absence of the return of symptoms of the disease – 0 (0,0%) versus 17 (3,6%), p=0,003. [2]采用和不采用 LRT 的 3 年 PFS 和 OS 分别为 31% 和 6% (p < 0·001) 和 41% 和 17% (p < 0·001)。 [1] 尽管睾丸水肿的形成频率没有统计学上的显着差异（0（0.0%）对 6（1.3%），p=0.185），但患者的状况在统计学上显着改善是由于使用创新的 PHELPS 技术而发现，包括没有疾病症状的复发 - 0 (0,0%) 对 17 (3,6%)，p = 0,003。 [2]
expedited partner therapy 快速伴侣治疗
Compared to the pre-expedited partner therapy group, the frequency of reinfection in the post-expedited partner therapy group was not statistically different (60/471 (13%) versus 61/419 (15%), OR 0. [1] Compared to the pre-expedited partner therapy group, the frequency of reinfection in the post-expedited partner therapy group was not statistically different (60/471 (13%) versus 61/419 (15%), OR 0. [2]与加急前伴侣治疗组相比，加急伴侣治疗后组的再感染频率没有统计学差异（60/471（13%）对 61/419（15%），OR 0. [1] 与加急前伴侣治疗组相比，加急伴侣治疗后组的再感染频率没有统计学差异（60/471（13%）对 61/419（15%），OR 0. [2]
% versus 46 % 与 46
Event-free survival in patients with i-lowLVM and appropriate-LVM was 76% versus 68% at 2-year, 55% versus 46% at 4-year, 33% versus 27% at 6-year, 20% versus 17% at 8-year, and 17% versus 11% at 10-year follow-up, respectively (p < 0. [1] The best-fit sustained implantation rates for age 33 compared to age 39 years were 86% versus 80% for day 5 good, 71% versus 62% for day 5 fair, 59% versus 55% for day 5 poor, and 81% versus 46% for all day 6. [2]i-lowLVM 和适当 LVM 患者的 2 年无事件生存率为 76% 对 68%，4 年 55% 对 46%，6 年 33% 对 27%，20% 对 17% 8 年随访时，17% 和 10 年随访时分别为 11%（p < 0. [1] 与 39 岁相比，33 岁的最佳持续植入率分别为 86% 对 80%（第 5 天良好）、71% 对 62%（第 5 天）、59% 对 55%（第 5 天差）和 81% 对第 6 天为 46%。 [2]
87 % 95 87 % 95
Pooled sensitivity and specificity were 87% (95% CI, 75%-93%) and 57% (95% CI, 37%-76%) for whole-body MRI, versus 64% (95% CI, 45%-79%) and 82% (95% CI, 75%-88%) for FDG PET/CT (sensitivity: p =. [1]全身 MRI 的综合敏感性和特异性分别为 87% (95% CI, 75%-93%) 和 57% (95% CI, 37%-76%)，而 64% (95% CI, 45%-79) %) 和 82% (95% CI, 75%-88%) 用于 FDG PET/CT (灵敏度: p =.